Medivation's Dimebon Maintains Statistically Significant Benefit on
All Five Efficacy Endpoints in Alzheimer's Disease Trial After One
Year of Therapy
- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of
Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...
Medivation to Host Conference Call to Discuss Top-Line 12-Month
Results From Dimebon Alzheimer's Disease Study
SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that it will hold a teleconferenceat 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line12-month results from its randomized, double-blind,placebo-controlled Phase 2 clinical trial of
Dimebon(TM), its leadproduct candidate, in Alzheimer's disease. Rachelle Doody, M.D., Ph.D., lead inve...
Medivation Announces Presentation of New Subset Analyses From
Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of
Neurology Annual Meeting
Company Conference Call Scheduled for Friday, May 4, at 9:00 a.m.Eastern Time to Discuss Data SAN FRANCISCO, May 03, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that new data from the mild andmoderate subgroups of Alzheimer's disease patients in the Company'ssix-month Phase 2 efficacy study of
Dimebon showed that bothsubgroups were improved compared with placebo-treated...
Medivation Announces First U.S. Presentation of Data From Dimebon
Phase 2 Alzheimer's Disease Trial at American Academy of Neurology
Annual Meeting
-- New Subset Analyses To Be Presented -- SAN FRANCISCO, April 24, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that data from the Company's Phase2 efficacy study of
Dimebon(TM) in Alzheimer's disease will bepresented for the first time in the United States at the AmericanAcademy of Neurology's 59th Annual Meeting in Boston on Thursday,May 3, at 4:15 p.m. Eastern time. T...
Medivation Announces Presentation of Full Top-Line Data From
Dimebon Six-Month Trial at Major International Alzheimer's Disease
Conference
SAN FRANCISCO, March 19, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that six-month results from itsrandomized, double-blinded, placebo-controlled Phase 2 efficacytrial of
Dimebon(TM) in patients with mild-to-moderate Alzheimer'sdisease demonstrated that patients treated with
Dimebon weresignificantly improved compared to patients taking placebo on allfive efficacy end...